Introduction
Angiogenesis is a critical event in tumor development (Hanahan and Folkman, 1996) . However, it does not occur in normal adult tissue except during the female reproductive cycle (Hanahan and Folkman, 1996) . These differences in angiogenesis have been mainly explained by upregulation of angiogenic genes such as vascular endothelial growth factor (VEGF) in response to hypoxia, paracrine factors or gene mutations in tumor tissue (Ferrara, 1999; Carmeliet and Jain, 2000) . Another explanation involves an increase in the availability of VEGF sequestered in the extracellular matrix (ECM) due to the action of a matrix metalloproteinase (MMP) that is concomitantly upregulated during carcinogenesis (Bergers et al., 2000) . However, the mechanism by which vascular quiescence is maintained in normal tissues, wherein VEGF is widely expressed (Berse et al., 1992; Hanahan and Folkman, 1996) , remains unclear. Several secreted proteins have been reported to bind and sequester VEGF (Kendall and Thomas, 1993; Gengrinovitch et al., 1995; Gupta et al., 1999; Inoki et al., 2002; Luque et al., 2003) . This type of regulation could account for the vascular quiescence in the presence of VEGF, although in most tissues except the cornea (Ambati et al., 2006) , the relevance of these proteins to vascular control has yet to be demonstrated.
MMPs are a family of extracellular proteinases targeting a variety of ECM proteins (Overall and Kleifeld, 2006) . They are implicated in promoting angiogenesis by remodeling the perivascular ECM and liberating angiogenic factors from the ECM (Roy et al., 2006) . While most MMPs are produced by stromal cells, such as fibroblasts, vascular cells and inflammatory cells, MMP-7 is primarily expressed by cancer cells (Overall and Kleifeld, 2006) . This may therefore implicate that MMP-7 acts as a specific signal from cancer cells to the stromal cell components necessary for tumor angiogenesis.
The specific characteristics of tumors and normal tissues are due to interactions between different cell types within each tissue. A common cellular component of both tissues is fibroblasts, which generate ECM components and paracrine factors (Kalluri and Zeisberg, 2006) . In tumors, stromal fibroblasts as well as cancer cells are a significant source of VEGF promoting angiogenesis (Hlatky et al., 1994; Fukumura et al., 1998; Dong et al., 2004) . Although the phenotypic changes in tumor fibroblasts are considered responsible for the angiogenic properties as distinct from those of normal fibroblasts (Orimo et al., 2005; Kalluri and Zeisberg, 2006) , fibroblasts from normal tissues also produce VEGF (Berse et al., 1992; Hlatky et al., 1994) . This suggests that a mechanism other than the regulation of VEGF expression may modulate fibroblast VEGF activity, and subsequently affect whether angiogenesis is triggered in those tissues. Since angiogenesis is a tumor-specific phenomenon, this mechanism may involve an interaction between fibroblasts and cancer cells.
We have investigated the angiogenic activity of fibroblasts in tumor and nontumor environments using human pancreatic cancer cells and human fibroblast strains. Our data show that VEGF secreted from some fibroblasts is intrinsically inactive, and that cancer cells reactivate this inactive form of VEGF, making it selectively available within the tumor microenvironment. As the molecular mechanisms for this cancerstroma interaction, we demonstrate that connective tissue growth factor (CTGF), which was shown to sequester VEGF in vitro , is involved in the inactivation of the VEGF from fibroblasts. We further show that MMP-7 from cancer cells is responsible for the reactivation of this inactive VEGF.
Results
Angiogenic activity of VEGF from fibroblasts in a tumor environment We examined the effect of several human fibroblasts differently expressing VEGF (Figure 1a ) on tumor xenografts in nude mice. Subcutaneous co-injection of human pancreas cancer Capan-1 cells with green fluorescent protein (GFP)-labeled human VA-13 fibroblasts or human WI-38 fibroblasts resulted in a significant increase in tumor growth (Figure 1b) , whereas no tumors were formed by injecting any of the fibroblast strains alone (data not shown). Immunohistochemical analysis showed that all GFP-labeled human fibroblast strains examined contributed to MMP-7 activates latent VEGF from fibroblasts T-K Ito et al tumor stroma formation (Figure 1c and data not shown). Macroscopic analysis and von Willebrand factor (vWF) immunostaining of the tumors containing VA-13 fibroblasts suggested that these fibroblasts promoted tumor angiogenesis (Figure 1c ). Co-culture experiments of Capan-1 cells and VA-13 fibroblasts showed no effect on Capan-1 cell proliferation (Figure 1d ), suggesting that VA-13 fibroblast-induced angiogenesis was due to a direct effect on vessels rather than an indirect effect that followed the acceleration of tumor growth by VA-13 fibroblasts.
To study the effect of VEGF from VA-13 fibroblasts on tumor angiogenesis, we used oligonucleotide small interfering RNA (siRNA). Introduction of VEGF siRNA into VA-13 fibroblasts blocked VEGF mRNA and protein expression as compared with control siRNA (Figure 1e and f) . VEGF suppression in VA-13 fibroblasts abolished the increased tumor growth (Figure 1g and h) and blocked the increased microvessel density induced by VA-13 fibroblasts (Figure 1i ). These results show that VEGF from VA-13 fibroblasts contributes to tumor angiogenesis and growth.
Angiogenic activity of VEGF from fibroblasts in a nontumor environment
We next examined the angiogenic activity of VEGF from VA-13 fibroblasts in a nontumor environment. Injection of VA-13 fibroblasts alone did not alter subcutaneous vascular structure compared with the noninjected left side (Figure 2a ). Consistent with these observations, VA-13 fibroblasts alone did not stimulate angiogenesis in chick chorioallantoic membranes (Figure 2b and c), showing that VA-13 fibroblasts have no proangiogenic effect in nontumor environments. We also performed an in vitro tube formation assay of human umbilical vein endothelial cells (HUVECs) with culture supernatant from VA-13 fibroblasts. With or without an anti-VEGF antibody, the supernatant failed to alter endothelial tube formation, in contrast to the positive effect of serum-free medium with recombinant human VEGF (Figure 2d and e). Taking into consideration the VEGF production in the VA-13 fibroblast supernatant (Figure 1f ), these findings suggest that VEGF from VA-13 fibroblasts may be inactivated in the nontumor environment and activated in the tumor environment, thus leading to the different angiogenic responses of VA-13 fibroblasts according to prevailing conditions.
Regulation of angiogenic activity of VEGF from fibroblasts by CTGF and MMP-7 If so, we would expect that VEGF from VA-13 fibroblasts would be sequestered in an inactive form by a binding protein. Previous reports have shown that some secreted proteins, including soluble VEGF receptor 1, platelet factor 4, thrombospondin, ADAMTS1 and CTGF, bind to VEGF and inhibit angiogenic activity (Kendall and Thomas, 1993; Gengrinovitch et al., 1995; Gupta et al., 1999; Luque et al., 2003; Inoki et al., 2002; Jang et al., 2004) . As one of these proteins, CTGF is typically expressed in fibroblasts (Brigstock, 1999) , we considered the possibility that CTGF might function as an inhibitor of VEGF from fibroblasts. It has also been reported that the angiogenic activity of VEGF suppressed by complex formation with CTGF is recovered through selective degradation of CTGF by some MMPs in vitro . Among such MMPs (MMP-1, MMP-2, MMP-3, MMP-7, MMP-9 and MMP-13), MMP-7 expression is upregulated selectively in cancer cells during tumor progression (Crawford et al., 2002) . Real-time PCR analysis demonstrated CTGF expression in all fibroblast strains examined ( Figure 3a ) and MMP-7 expression exclusively in Capan-1 cells (Figure 3b and c). Taken together, these reports and data led us to hypothesize that VEGF from VA-13 fibroblasts is inactivated by CTGF, and that MMP-7 from Capan-1 cells restores the angiogenic activity.
To test this hypothesis, we performed tube formation assays with culture supernatant from VA-13 fibroblasts. MMP-7 treatment elicited the angiogenic activity in the supernatant, but MMP-7 itself had no effect (Figure 3d ). This elicited activity was abolished by an anti-VEGF antibody (Figure 3d) , showing that MMP-7 activates the latent activity of the VEGF from VA-13 fibroblasts. This activity was also inhibited by the addition of CTGF after blocking MMP-7 activity with either tissue inhibitor of metalloproteinase-1 (TIMP-1) or an anti-MMP-7 antibody after the MMP-7 treatment to avoid the degradation of added CTGF (Figure 3d ). In contrast, CTGF exhibited no significant activity when added to serum-free media or the supernatant without MMP-7 treatment (Figure 3d ), suggesting that CTGF itself had no significant activity on this tube formation assay. These data show that CTGF inactivates the angiogenic activity of VEGF from human fibroblasts.
We examined whether these mechanisms work in the tumor xenografts by using CTGF siRNA for VA-13 fibroblasts ( Figure 3e ) and MMP-7 siRNA for Capan-1 cells (Figure 3f ). The stimulating effects of VA-13 fibroblasts on tumor growth and angiogenesis were abrogated when MMP-7 expression in Capan-1 cells was suppressed (Figure 3g and h). CTGF suppression in VA-13 fibroblasts restored the tumor stimulating effects that otherwise would have been abolished by MMP-7 suppression in Capan-1 cells (Figure 3g and h) . As the effects of VA-13 fibroblasts were mediated by VEGF (Figure 1h and i), these results indicate that MMP-7 from human cancer cells activates CTGFinactivated VEGF from human fibroblasts in a tumor environment.
We further investigated whether these mechanisms can also apply in primary fibroblasts isolated from human pancreas cancer. We first analysed VEGF, CTGF and MMP-7 expression in tumor-associated fibroblasts from two pancreas cancer patients. Consistent with the results for VA-13 fibroblasts, there was high expression of VEGF and CTGF (Figure 4a and b) , and no expression of MMP-7 (data not shown) in these primary fibroblasts. Using one strain of these fibroblasts, we subsequently performed tube formation assays. The angiogenic activity of the VEGF from the primary fibroblasts was activated by MMP-7 and inactivated by CTGF (Figure 4c ), indicating that VEGF from primary tumor-associated fibroblasts also contributes to tumor angiogenesis through these activation mechanisms.
Regulation of angiogenic activity of VEGF in colorectal tissue by MMP-7 and other MMPs As these molecules are secreted proteins and work extracellularly, we speculated that these mechanisms may also function at the tissue level. We analysed the expression of VEGF, CTGF, MMP-7 and other MMPs in normal and tumor samples from 37 colorectal cancer patients. We analysed colorectal cancers because angiogenesis in colorectal cancers is thought to be VEGF dependent to some extent, because of the therapeutic effectiveness of an anti-VEGF monoclonal antibody (McCarthy, 2003) , and therefore expression patterns of these molecules might involve a shift from a normal to a malignant phenotype with newly developing vasculature. There was persistent expression of VEGF in normal tissues, although it was upregulated 2.5-fold in MMP-7 activates latent VEGF from fibroblasts T-K Ito et al tumors (Figure 5a ). CTGF was constitutively expressed, and no significant change was observed (Figure 5b ). The most marked difference was observed in MMP-7 expression. MMP-7 was barely detected in normal tissues, but was 138-fold in tumors (Figure 5c ). There was also a sharp increase in MMP-1 and MMP-3 levels in tumors, no significant change in MMP-2 and MMP-9 levels ( Supplementary Figure 1) , and almost no detectable amounts of MMP-13 (data not shown). These expression patterns suggest that, in addition to the increased expression of VEGF, upregulated MMP-7, MMP-1 and MMP-3 may regulate the switch from MMP-7 activates latent VEGF from fibroblasts T-K Ito et al vascular quiescence to angiogenesis in the human colorectum. Finally, we studied the relevance of these molecules to tumor angiogenesis in these patients. As vWF expression is induced by VEGF in endothelial cells and reflects tumor angiogenesis in the colorectum (Zanetta et al., 2000) , we evaluated vWF mRNA expression in tumor samples as a measure of tumor angiogenesis. We divided colorectal cancer patients into four groups according to the expression patterns of VEGF and MMP-7. We did not consider the CTGF expression level because CTGF was highly expressed in both tumors and normal tissues (Figure 5b ). We found that only the group with high VEGF and high MMP-7 expression revealed elevated expression of vWF (Figure 5d ). This was confirmed by examining the expression of another endothelial marker, CD31 (Figure 5e ). We also analysed MMP-1 and MMP-3 and obtained similar results as for MMP-7 (Supplementary Figure 2) , although neither the expression of MMP-1 nor MMP-3 correlated with that of MMP-7 (Spearman's correlation coefficient ¼ 0.20 and 0.11, respectively; data not shown). The tumors that are VEGF positive and positive for all three MMPs showed a stronger association with vWF and CD31 expression (Supplementary Figure 3) , which suggests that these MMPs may work in a cooperative and compensatory manner. Furthermore, immunohistochemical analysis revealed that vWF þ clusters were observed more frequently in tumors with high VEGF and MMP-7 expression than those with high VEGF and low MMP-7 expression (Figure 5f ). Collectively, these studies indicate that MMP-7 and other MMPs may trigger the angiogenic switch involving VEGF in tumor tissue, supporting the idea that these MMPs activate CTGF-sequestered VEGF within the tissue.
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Discussion
We report that the interaction between human cancer cells and fibroblasts triggers the VEGF angiogenic switch in fibroblasts in experimental tumors in nude mice. We have demonstrated that VA-13 fibroblasts expressing a high level of VEGF do not trigger angiogenesis within nontumor tissues, whereas they promote angiogenesis in a VEGF-dependent manner in Capan-1 tumor xenografts. VEGF released from such fibroblasts is intrinsically inactive in the absence of ECM sequestration, whereas Capan-1 cancer cells are involved in making the VEGF available, leading to tumor-selective exploitation of VEGF. We identified 
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CTGF as the factor produced by VA-13 fibroblasts that inactivates VEGF, and MMP-7 as the factor produced by Capan-1 cancer cells that reactivates the inactive form of VEGF. We also showed that MMP-7
activates and CTGF inactivates the VEGF released from primary fibroblasts isolated from human pancreas cancer in an in vitro assay. The concept that a cancer-cell-specific proteinase regulates VEGF activity MMP-7 activates latent VEGF from fibroblasts T-K Ito et al within the tumor stroma provides another mechanism by which tumor-associated fibroblasts reveal angiogenic activity not normally present in fibroblasts.
We have shown correlative data in which high levels of expression of MMP-7, MMP-1 and MMP-3 along with VEGF are associated with increased expression of angiogenesis markers in the human colorectum, where CTGF is constitutively expressed. In addition, whereas these three MMPs were upregulated in tumor tissues, the expression of MMP-2 and MMP-9 was similar to that seen in normal tissues. The proteolytic activity of MMP-2 and -9 to CTGF has been described as extremely low in vitro , suggesting that these MMPs may not be active in CTGF cleavage in tissues. As well as in the colorectum, VEGF and CTGF are widely expressed in tumors and normal tissues of many organs (Hanahan and Folkman, 1996; Brigstock, 1999) . MMP-7 is selectively expressed in many tumors, including gastric, pancreatic, breast, prostate, liver, lung, skin, head and neck carcinomas (Ii et al., 2006) . Although the interaction between these factors is yet to be demonstrated, the extracellular communication in VEGF regulation reported here may also operate at the tissue level.
The physiological action of MMPs varies between species and target organs (Overall and Kleifeld, 2006) . Our data suggest a regulation of VEGF activity by CTGF and MMP-7 in human cells and tissues. Human MMP-7 and other MMPs do not cleave the predominant isoform of VEGF (VEGF 165 ) in vitro (Keyt et al., 1996; Hashimoto et al., 2002) , which leads to selective degradation of CTGF and the release of VEGF activity . In contrast, MMP-7 and other MMPs modulate bioactivity of the corresponding isoform of mouse VEGF through intramolecular cleavage (Lee et al., 2005) . Thus, it is likely that VEGF regulation by MMPs is quite different in mice and humans. MMP-9 from leukocytes has been described as relevant for VEGF release from the ECM and/or tumor angiogenesis in several mouse models of cancer such as cervical cancer (Giraudo et al., 2004) , islet cell tumor (Bergers et al., 2000) , skin cancer (Coussens et al., 1999) and neuroblastoma (Jodele et al., 2005) . In these models, VEGF may not be sequestered in the ECM with CTGF because MMP-9 is not competent in CTGF cleavage as cited above, indicating alternative mechanisms according to the type of tumor. The relevance of other molecules that bind VEGF to angiogenesis triggered by MMPs should be tested for better understanding of VEGF regulation in the body.
MMP-7 was reported to induce HUVEC proliferation (Huo et al., 2002) . As a possible underlying mechanism, this effect could be mediated by degradation of VE-cadherin and nuclear accumulation of b-catenin in HUVECs (Ichikawa et al., 2006) . Additionally, in light of the secretion of VEGF (Huo et al., 2002) and CTGF (Brigstock, 1999) by HUVECs, the HUVEC proliferation induced by MMP-7 could also be explained by liberation of CTGF-sequestered VEGF, helping endothelial cells use the self-made VEGF.
Similar to tumor formation, wound healing is often characterized by angiogenesis and the recruitment of fibroblasts (Dvorak, 1986) . Fibroblasts synthesize ECM components and paracrine factors, including VEGF and CTGF. These molecules would probably be sequestered in the ECM, because they bind to fibronectin (Wijelath et al., 2002; Chen et al., 2004) and heparin (Ferrara and Henzel, 1989; Brigstock et al., 1997) . Furthermore, MMP-7 or other MMPs are upregulated in injured tissues (Parks, 1999) , suggesting the potential application of our results in wound healing. Our study indicates the potential role of fibroblasts as a reservoir of angiogenic factors, to keep them inactive in the extracellular environment in case of an emergency that requires quick regenerative responses, and thus providing rigorous regulation of angiogenesis.
Materials and methods
Human cell lines
Human SV40-transformed fibroblast cell lines VA-13, IMR-90SV, MRC-5SV1TG1 (RIKEN, Tsukuba, Japan) and KM-104 (a gift from Dr K Harigaya, Chiba University, Japan) were transfected with the pMX-GFP vector (a gift from Dr T Kitamura, University of Tokyo, Japan), and GFP-positive cells were sorted as described previously (Ishii et al., 2005) . These cell lines and the nontransformed human fibroblast cell line WI-38 (RIKEN) were cultured in a-minimal essential medium (aMEM) (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS). Human pancreas cancer cell line Capan-1 (ATCC, Manassas, VA, USA) was cultured in Dulbecco's modified Eagle's medium (Sigma, St Louis, MO, USA) with 20% FBS. HUVECs (Dainippon Pharmaceutical, Osaka, Japan) were maintained in MCDB131 (Invitrogen) supplemented with 10% FBS, 10 ng/ml basic fibroblast growth factor and 10 mmol/l glutamine on a collagen-coated dish. For all experiments, HUVECs were used at passage 5-7. All cells were cultured in a humidified atmosphere of 95% air and 5% CO 2 at 371C.
Tissue samples
Primary fibroblasts were obtained from surgical specimens from pancreas cancer patients, and were cultured in aMEM with 10% FBS. Normal and tumor tissues were obtained from surgical specimens from colorectal cancer patients. The tissues were collected at the time of surgery and immediately stored in TRIzol Invitrogen at À801C until they were used for RNA extraction. These patients had undergone surgical resection in the National Cancer Center Hospital East. All tissue samples were collected after obtaining informed consent according to institutional ethical guidelines.
Statistical analysis
Data are expressed as means7s.d. Data were tested for normality using the Kolmogorov-Smirnov test. Equality of variance was tested using the F-test for a single pairwise comparison and Bartlett's test for multiple pairwise comparisons. Statistical significance was assessed using two-tailed Student's t-tests or Mann-Whitney U-test according to the normality of the data for a single pairwise comparison, and post hoc Dunnett's test following analysis of variance or Kruskal-Wallis test according to the variance of the data for multiple pairwise comparisons. Differences were considered significant if Po0.05.
Tumor xenografts in nude mice, immunohistochemistry, microvessel density analysis, co-culture assay, real-time RT-PCR, RNA interference, VEGF enzyme-linked immunosorbent assay, tube formation assay, chick chorioallantoic membrane assay Detailed Materials and methods used in this study can be found in the Supplementary Information.
